Why cheap everyday medicines are proving hardest to keep on pharmacy shelves

Supply problems affecting diabetes, asthma, blood pressure and cholesterol medicines can disrupt stable treatment, with older generic drugs particularly vulnerable to manufacturing and distribution failures.

Everyday medicines are often the ones most exposed when supply chains falter, and that is exactly why shortages in drugs for diabetes, asthma, high blood pressure and cholesterol can be so disruptive. The French patient group MedFrance says the problem is not limited to headline-grabbing treatments: it also affects old, widely used drugs that are cheap to make, heavily prescribed and therefore easy to overlook until they disappear from the shelf.

For patients, the loss of a familiar medicine is rarely a minor inconvenience. A stable diabetes regimen can be upset by a substitution, an inhaler may need a different technique, and long-term protection against complications can be interrupted by a gap in treatment. What looks like a routine pharmacy issue can quickly become a medical one, especially when the medicine in question is taken every day and has been part of a patient’s life for years.

The reason these shortages happen is often structural rather than dramatic. The US Food and Drug Administration says drug shortages can stem from manufacturing problems, quality failures, shipping delays and discontinuations, and it maintains a database to track affected products, alternatives and expected resupply dates. In practice, a problem at one factory, or with one ingredient, can ripple through the market far beyond the original fault.

That fragility is magnified when a medicine is inexpensive and margins are tight. MedFrance says older generic products are particularly exposed because they are produced in large volumes but often bring limited profit, which can make it less attractive for companies to maintain extra stock or multiple manufacturing sites. In that environment, even a brief production disturbance can leave pharmacies with empty shelves and patients with nowhere immediate to turn.

The wider US picture shows that shortages remain a persistent issue. The American Society of Health-System Pharmacists said active shortages were still trending upwards through June 2026, with nearly half of new shortages in that year involving sole-source products, meaning there is only one supplier. ASHP also noted that controlled substances account for a meaningful share of active shortages, underlining that the problem is not confined to one category of medicine.

Although many shortages are most visible in hospitals and specialist care, the impact on chronic disease management can be just as serious. Drugs.com’s shortage tracking highlights how supply problems can delay treatment and increase the risk of medication errors and poorer outcomes. In the community pharmacy setting, the effect is often quieter but no less important: a patient may be switched to another dose, another brand or a different device, and may need clear instructions to use it safely.

That is why professional advice matters so much when a prescription cannot be filled. Pharmacists can check whether the problem is with a specific strength, a particular formulation or the entire medicine, and they may be able to suggest a suitable equivalent or contact the prescriber. Patients, meanwhile, are generally advised not to adjust doses on their own, not to borrow medicine from someone else and not to wait until the final tablet is gone before seeking help.

MedFrance says the best response is practical and calm: renew prescriptions early, identify exactly what is unavailable, and work through alternatives with a pharmacist or doctor rather than improvising. The broader lesson is that the cheapest medicines are not necessarily the easiest to replace. When they fail, the consequences can be felt in blood sugar control, breathing, blood pressure and long-term cardiovascular risk, making a routine prescription suddenly feel very fragile indeed.